1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Multiple Sclerosis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

Multiple Sclerosis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

  • December 2020
  • 115 pages
  • ID: 6001590
  • Format: PDF
  • Mordor Intelligence LLP
Up to $750 off Until Feb 28th 2021

Summary

Table of Contents

Search Inside

The market studied is expected to witness a rapid growth rate in the future, owing to factors, such as the rising prevalence of multiple sclerosis (MS) and the growing focus of companies on pipeline products for MS.

- Big pharmaceutical companies have been investing heavily in the drug development process and are planning to target as many indications as possible, in order to cater to a large number of customers. Owing to this, the MS market has also been benefiting. For instance, the drugs being developed for multiple sclerosis include the drugs for Relapsing-remitting MS, Secondary progressive MS, Primary progressive MS, and Myelin repair or neuroprotection.
- Biogen, a leading player in the market studied has been developing Diroximel fumarate, which is currently in phase III of development; similarly, Novartis has been developing Ofatumumab, which is also in Phase III.
- Similar to the above-mentioned companies, there have been other pharmaceutical players, such as Pfizer Inc., which have been developing drugs for MS. This indicates that pipeline drugs for MS may boost the studied market’s growth in the forecast period.

Key Market Trends
The Oral Route of Administration is Expected to Witness Rapid Growth in Future

Classical multiple sclerosis (MS) treatments using first-line injectable drugs, even though they have been widely applied, remain to be a foremost concern in terms of therapeutic adherence and efficacy. Novel oral drugs, recently approved for the treatment of MS, represent significant advances in the therapy. The oral route of administration evidently supports patient satisfaction and increases therapeutic compliance.

If someone is not comfortable with needles, there are oral options for treating MS. Taken daily or twice daily, oral medications require one to maintain a regular dosing schedule. These are the easiest to be self-administered.

The currently available oral multiple sclerosis drugs include Aubagio (teriflunomide), Gilenya (fingolimod), and Tecfidera (dimethyl fumarate).

In March 2019, the US Food and Drug Administration approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

North America to Dominate the Market

The market for multiple sclerosis therapeutics is expected to show high growth in the North America region, which is majorly attributed to the presence of key players and the rising prevalence of the disease in this region. The United States is the major market for companies, such as Biogen, Novartis AG, and Sanofi SA, among others. Therefore, these companies have been focusing more on establishing their new drugs in this market studied, which ultimately has been contributing to the growth of this region.

Furthermore, as per the National Multiple Sclerosis Society, Canada is a country with the highest prevalence of MS in the world (291 per 100,000). In the case of the United States, the National MS Society estimated that there are around 1 million people in the country living with MS.

Hence, due to the high prevalence and presence of the key players, North America is expected to dominate the market studied.

Competitive Landscape
The market for MS therapeutics is consolidated, as there are few players in this market. These companies are the big pharmaceutical companies that have been focusing on pipeline drugs for multiple sclerosis. With the rising R&D investment in the pharmaceutical industry, it is believed that more companies may enter the market studied in the future, and the competition may increase.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
10% Off

$4250

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Dermatomyositis - Pipeline Review, H2 2020

  • $ 2000
  • November 2020
  • 149 pages

Dermatomyositis - Pipeline Review, H2 2020 Summary latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Pipeline Review, H2 2020, provides an overview of the Dermatomyositis ...

  • World
  • Pharmaceutical
  • Neurological Disorder
  • Industry analysis
  • Drug Approval
  • Pharmaceutical Registrations

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on